ANI Pharmaceuticals Q3 Revenue Reaches $290.777 Million
Q3 revenue was $290.777 million, compared with an IBES estimate of $280.2 million.
Related stories
Lincoln International Reports Q3 2026 Financial Results
Lincoln International reported third-quarter and year-to-date revenues of $293.7 million and $677.1 million, respectively.
M impact | EQUITY | Nov 05, 2026, 12:15 PM UTC
illumin Holdings Reports Q3 Revenue of CA$42.7M
Q3 revenue was CA$42.7 million, versus a FactSet estimate of CA$42.6 million.
M impact | EQUITY | Nov 05, 2026, 12:09 PM UTC
Appian Announces Third-Quarter 2026 Financial Results
M impact | EQUITY | Nov 05, 2026, 12:06 PM UTC
REGENXBIO Reports Third-Quarter 2026 Results
REGENXBIO reported third-quarter 2026 financial results and operational highlights. Its RGX-202 BLA submission for Duchenne muscular dystrophy is on track for Q1 2027, with potenti
M impact | EQUITY | Nov 05, 2026, 12:05 PM UTC
Bob's Discount Furniture Q3 earnings snapshot
M impact | EQUITY | Nov 05, 2026, 12:05 PM UTC
ANI Pharmaceuticals raises 2026 adjusted EPS view to $9.37–$9.71
M impact | EARNINGS | Nov 05, 2026, 12:05 PM UTC